Ajouter à une liste

Communiqués SWIE ACQUPAR

Actions

IVCP

KYG638361033

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
3,330 ^USD	-3,20%		-3,20%	-68,29%

13/12/24	Acquisition de Swiftmerge et fusion d'AleAnna Energy achevées	MT
13/12/24	AleAnna Energy, LLC a réalisé l'acquisition de Swiftmerge Acquisition Corp. (NasdaqCM:IVCP) auprès de Swiftmerge Holdings, LLC, Farallon Capital Management, Polar Asset Management Partners Inc, Meteora Capital, LLC et d'autres dans le cadre d'une opération de fusion inversée.	CI

Communiqués

19/12/24	SWIE ACQUPAR : ALEANNA ENERGY, LLC CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED) Form 8 K	PU
13/12/24	AleAnna, Inc. Announces Completion of Business Combination between Swiftmerge Acquisition Corp. and AleAnna Energy, LLC	AQ
13/12/24	Swiftmerge Acquisition : Proxy Results Form 8 K	PU
05/06/24	Swiftmerge Acquisition : AleAnna, A Next Generation European Natural Gas Company, Signs Agreement to be Publicly Listed Through Combination with Swiftmerge Acquisition Corp Form 8 K	PU
24/08/23	Swiftmerge Acquisition : Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report - Form 8-K	PU
11/08/23	HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.	BU
15/06/23	SWIFTMERGE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
12/06/23	Swiftmerge Acquisition : Adjournment of Extraordinary General Meeting - Form 8-K	PU
16/05/23	SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
24/04/23	HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment	BU
21/04/23	SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21/04/23	SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
10/11/22	SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
22/08/22	SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
19/05/22	SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
08/04/22	SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Les meilleurs outils réservés aux abonnés pour augmenter la performance de vos investissements !